Forbes  Jun 21  Comment 
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative...
Motley Fool  Jun 14  Comment 
Celgene Corp, Regeneron Pharmaceuticals, and Gilead Sciences boast catalysts that can make them portfolio-worthy.
Benzinga  Jun 10  Comment 
Like most biopharmaceuticals, Regeneron Pharmaceuticals Inc (NASDAQ: REGN) has had a tough 2016. Since the year started, the stock has lost about 31.5 percent of its value. Moreover, in the past five trading sessions, shares tumbled more than 7...
newratings.com  Jun 6  Comment 
PARIS (dpa-AFX) - Regeneron Pharmaceuticals Inc. (REGN) and Sanofi (SNYNF, SNY) announced that a one-year Phase 3 study, known as LIBERTY AD CHRONOS, evaluating investigational dupilumab met its primary and key secondary endpoints. In the study,...
Benzinga  Jun 1  Comment 
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) shares are trading higher by $9 at $407.93 in Wednesday's session. The catalyst for the rally is favorable interim data from Stage 2 proof concept trial of Evinacumab. After a flat open, it went...
Benzinga  May 31  Comment 
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) revealed that positive preliminary results from an ongoing proof-of-concept trial of evinacumab (REGN1500) in patients with Homozygous Familial Hypercholestrolemia (HoFH) were presented at the 84th...
Motley Fool  May 27  Comment 
One is growing fast; the other is already gigantic, but which is the better buy now?
New York Times  May 26  Comment 
The biotechnology company will sharply increase funding for the longtime high school contest with which Intel ended its relationship last year.
Motley Fool  May 17  Comment 
Both companies promise upside potential, but which one is the better choice for new money today?


Since its inception in 1988, Regeneron Pharmaceuticals, Inc. (REGN) has operated as a research and development (R&D) company engaged in the development of drugs for the treatment of various diseases. Regeneron's goal is to become a fully integrated biopharmaceutical company by commercializing these drugs. The company has advanced a few of its pipeline drugs into clinical stage development. The leading drug programs in this regard are IL-1, for inflamatory disease, and VEGF, for cancer and eye diseases. Revenues consist of R&D collaboration payments from development partner Sanofi-Aventis and contract manufacturing payments from pharmaceutical giant Merck for a pediatric vaccine. Manufacturing agreement expired in October 2006. From 2007, revenue will mainly derive from collaboration with Sanofi-Aventis and Bayer and from technology transfers.

Regeneron is cururently based in Tarrytown, NY. In December 2006, the company signed a 15-year lease with BioMed Realty Trust, Inc. for a new corporate headquarters and research and development complex to be constructed adjacent to its current facility at the Landmark at Eastview in the Town of Greenburgh in Westchester County, New York. Regeneron also has the option to extend the lease for three additional 5-year periods. The new facilities will be constructed by BioMed Realty Trust over the next two years.

The Platform Techonology

Regeneron's most important propriatary technology is Trap Technology utilizing engineered antibody techniques. The decoy receptors (Traps) are composed of fusions between two distinct receptor components and a portion of an antibody molecule called the "Fc region", resulting in the generation of blockers with markedly increased affinity over that offered by single component reagents. Regeneron has applied this proprietary Trap technology to create a number of therapeutic candidates such as the IL-1 Trap and the VEGF Trap. The company also developed Velocigene/VelocImmune Technology which allows custom and precise manipulation of very large sequences of DNA to produce a highly customized knock-out of a specified target gene and accelerates the production of knock-out and transgenic expression models without using either positive/negative selection or isogenic DNA.


Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki